menu
    • menu

    Company profile for Aldeyra Therapeutics

    NEW Drugs in Dev: 6
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammati...
    Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aldeyra TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Aldeyra Therapeutics TM, 131 Hartwell Avenue, Suite 320 Lexington, MA 02421
    Telephone
    Telephone
    (781) 761-4904
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aldeyra.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aldeyra Extends Reproxalap Nda PDUFA For Dry Eye Disease
    Aldeyra Extends Reproxalap Nda PDUFA For Dry Eye Disease

    15 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251215293677/en/Aldeyra-Therapeutics-Announces-PDUFA-Extension-of-the-New-Drug-Application-of-Reproxalap-for-the-Treatment-of-Dry-Eye-Disease

    BUSINESSWIRE
    15 Dec 2025
    Share Share
    Aldeyra Expands RASP to CNS Diseases, Updates Reproxalap
    Aldeyra Expands RASP to CNS Diseases, Updates Reproxalap

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113748228/en/Aldeyra-Therapeutics-Announces-Expansion-of-RASP-Platform-to-Include-Central-Nervous-System-Diseases-and-Provides-Updates-on-Reproxalap-at-Research-Development-Webcast

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    Aldeyra Therapeutics Joins Jefferies Global Healthcare Conference
    Aldeyra Therapeutics Joins Jefferies Global Healthcare Conference

    11 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251111355562/en/Aldeyra-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference-in-London

    BUSINESSWIRE
    11 Nov 2025
    Share Share
    Aldeyra Therapeutics Hosts R&D Webcast On Nov
    Aldeyra Therapeutics Hosts R&D Webcast On Nov

    06 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251106091181/en/Aldeyra-Therapeutics-to-Host-Research-Development-Update-Webcast-Event-Scheduled-for-Thursday-November-13-at-800-a.m.-ET

    BUSINESS WIRE
    06 Nov 2025
    Share Share
    Aldeyra Cans RASP Asset, Advances Two Pipeline Candidates
    Aldeyra Cans RASP Asset, Advances Two Pipeline Candidates

    29 Oct 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/aldeyra-cans-rasp-asset-brings-forward-two-others-in-pipeline-shakeup

    BIOSPACE
    29 Oct 2025
    Share Share
    Aldeyra drops and swaps RASP assets in response to data
    Aldeyra drops and swaps RASP assets in response to data

    28 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251028764760/en/Aldeyra-Therapeutics-Announces-Positive-Results-from-Phase-2-Clinical-Trial-in-Alcohol-Associated-Hepatitis-Focuses-RASP-Product-Candidate-Pipeline-on-Next-Generation-Molecules

    BUSINESSWIRE
    28 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search